Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India.
Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India.
J Clin Lipidol. 2020 Jan-Feb;14(1):35-45. doi: 10.1016/j.jacl.2019.12.010. Epub 2020 Jan 9.
Familial hypercholesterolemia (FH), an autosomal codominant disorder characterized by very high low-density lipoprotein cholesterol, is strongly associated with premature coronary artery disease.
Molecular landscape of FH in Asian Indians is not well studied, although this ethnic group comprises a large proportion of the world population. Knowledge of mutations in these groups is useful for identifying persons affected with FH, saving their lives, and cascade screening in their relatives.
Potential cases of FH (n = 100) were identified by criteria adapted for the Indian population from Dutch Lipid Clinic Network criteria. Pathogenic variants were analyzed in LDLR, APOB 100 (exons 26 and 29), PCSK9, and APOE genes using Sanger sequencing and multiplex ligation-dependent probe amplification technique. Cases in whom there were no pathogenic variants were tested by next-generation sequencing using a targeted panel of genes.
Thirty-eight pathogenic variants were identified in 47 of 100 unrelated probands. Of these variants, 33 were identified in LDLR, 3 in APOB, and 2 in PCSK9 genes. Ten pathogenic variants were novel. Mutations were detected in 91.4% of those subjects classified as definite, 40% as probable, and in 18.8% as possible FH cases based on modified Dutch Lipid Clinic Network criteria. A likely founder mutation in intron 10 (c.1587-1G>A) of LDLR gene was observed in 6 North Indian families. The conventional pathogenic variants in APOB and PCSK9 genes and those previously reported in LDLR gene among Asian Indians were not detected in this cohort.
This study demonstrates genetic heterogeneity of FH in India. The variants observed were different from those described in Western populations. Next-generation sequencing technology helped identify new mutations in APOB gene, suggesting that in less-studied populations, it is better to sequence the whole gene rather than test for specific mutations.
家族性高胆固醇血症(FH)是一种常染色体显性遗传疾病,其特征为极低密度脂蛋白胆固醇水平非常高,与早发性冠状动脉疾病密切相关。
尽管亚洲印第安人在世界人口中占很大比例,但他们的 FH 分子图谱尚未得到充分研究。了解这些人群中的突变对于识别受 FH 影响的个体、挽救其生命以及对其亲属进行级联筛查非常有用。
通过适用于印度人群的标准,从荷兰脂质诊所网络标准中确定了潜在的 FH 病例(n=100)。使用 Sanger 测序和多重连接依赖性探针扩增技术分析 LDLR、APOB 100(外显子 26 和 29)、PCSK9 和 APOE 基因中的致病性变异。对于没有致病性变异的病例,使用靶向基因的下一代测序进行测试。
在 100 名无关先证者中,发现了 38 个致病性变异,其中 33 个在 LDLR 基因中,3 个在 APOB 基因中,2 个在 PCSK9 基因中。有 10 个致病性变异是新发现的。根据改良的荷兰脂质诊所网络标准,在被归类为明确、可能和可能 FH 病例的 91.4%、40%和 18.8%的受试者中检测到突变。在 6 个北印度家庭中观察到 LDLR 基因内含子 10(c.1587-1G>A)中的一个可能的创始人突变。在这个队列中,没有检测到亚洲印第安人 APOB 和 PCSK9 基因中的传统致病性变异以及 LDLR 基因中先前报道的变异。
本研究表明印度 FH 存在遗传异质性。观察到的变异与西方人群中描述的变异不同。下一代测序技术有助于识别 APOB 基因中的新突变,这表明在研究较少的人群中,最好对整个基因进行测序,而不是检测特定的突变。